Stockscreener 앱 받기
11.74
3.62%
0.41
시간 외 거래:
11.75
0.010
+0.09%
전일 마감가:
$11.33
열려 있는:
$11.24
하루 거래량:
1.96M
Relative Volume:
0.81
시가총액:
$3.48B
수익:
$423.49M
순이익/손실:
$-147.07M
주가수익비율:
-18.34
EPS:
-0.64
순현금흐름:
$-88.03M
1주 성능:
+2.18%
1개월 성능:
+10.75%
6개월 성능:
+12.88%
1년 성능:
+1.38%
1일 변동 폭
$11.21
$11.75
1주일 범위
$11.21
$11.75
52주 변동 폭
$9.02
$14.57
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(215) 921-7600
주소
3675 MARKET STREET, PHILADELPHIA, NJ
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 개시 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 재개 | Goldman | Neutral |
| 2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 재개 | BTIG Research | Buy |
| 2021-05-27 | 개시 | Needham | Hold |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-17 | 개시 | H.C. Wainwright | Buy |
| 2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 개시 | Janney | Buy |
| 2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 개시 | Citigroup | Neutral |
| 2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
| 2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
| 2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 개시 | BofA/Merrill | Buy |
| 2016-04-14 | 개시 | Robert W. Baird | Neutral |
| 2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
| 2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
Amicus Therapeutics Q3 2024 Earnings Preview - MSN
Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - Yahoo Finance
Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World
Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat
abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Wednesday - MarketBeat
Semanteon Capital Management LP Invests $1.13 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy - Defense World
Pompe Disease Market on Track for Major Expansion by 2034, - openPR
Pompe Disease Market on Track for Major Expansion by 2034, According to DelveInsight | Asklepios Biopharma, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark - The Globe and Mail
(FOLD) Proactive Strategies - Stock Traders Daily
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Bank of America - Defense World
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% - MSN
Creative Planning Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
What is Zacks Research’s Estimate for FOLD Q3 Earnings? - Defense World
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold - Seeking Alpha
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - MSN
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva - MSN
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Teva settles patent litigation with Amicus (TEVA:NYSE) - Seeking Alpha
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Zacks Research Issues Optimistic Outlook for FOLD Earnings - MarketBeat
What is Zacks Research’s Estimate for FOLD Q2 Earnings? - Defense World
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva - GlobeNewswire
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU - Benzinga
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpHere's Why - MarketBeat
Amicus announces settlement of Galafold patent litigation with Teva - TipRanks
Amicus Therapeutics settles patent litigation with Teva - Investing.com
Amicus Therapeutics settles patent litigation with Teva By Investing.com - Investing.com Australia
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Yahoo Finance
Amicus Therapeutics Shares Rise After Lawsuit Settlement, Deal With Teva - MarketWatch
Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2025 Earnings of $0.01 Per Share, Zacks Research Forecasts - MarketBeat
SG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Taking on analysts’ expectations and winning: Amicus Therapeutics Inc (FOLD) - SETE News
Morgan Stanley Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $18.00 - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Cut to Hold at StockNews.com - MarketBeat
Gaucher’s Disease Treatment Industry to Witness an Outstanding Growth by 2034 |Amicus Therapeutics, Inc., Novartis AG, S – IndiaPolitics.com - IndiaPolitics.com
Analyzing Amicus Therapeutics Inc (FOLD) After Recent Trading Activity - Knox Daily
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):